Asia Pacific Cell Therapy Market Size, Share & Trends Report

Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report By Use-type (Clinical-use, Research-use), By Therapy Type (Autologous, Allogeneic), And Segment Forecasts, 2021 - 2028

  • Published Date: Jun, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68039-450-4
  • Format: Electronic (PDF)
  • Historical Data: 2017 - 2019
  • Number of Pages: 135

Table of Contents

Chapter 1 Methodology And Scope
                 1.1 Research Assumptions
                 1.2 Research Methodology
                 1.3 Information Procurement
                 1.4 Information or Data Analysis
                 1.5 Market Formulation & Validation
                 1.6 Regional & Country-level Market: CAGR Calculation
                 1.7 Market Study
                       1.7.1 Product mapping, By regulatory status
                            1.7.1.1 Products with RMAT Designations
                            1.7.1.2 Product study
                                  1.7.1.2.1 MACI (Vericel Corporation)
                                  1.7.1.2.2 LAVIV (Azficel-T) (Fibrocell Technologies)
                       1.7.2 Market study, by Therapeutic Area
                            1.7.2.1 malignancies
                       1.7.3 Regional analysis
                            1.7.3.1 Region-wise market: Base estimates
                 1.8 Objectives
                       1.8.1 Objective 1
                       1.8.2 Objective 2
Chapter 2 Executive Summary
                 2.1 Market Snapshot
Chapter 3 Cell Therapy Market Variables, Trends, And Scope
                 3.1 Market Trends and Outlook
                 3.2 Market Segmentation and Scope
                 3.3 Market Dynamics
                       3.3.1 Market driver analysis
                            3.3.1.1 Rise in number of clinical studies for cellular therapies in Asia Pacific
                            3.3.1.2 Expanding regenerative medicine landscape in Asian countries
                            3.3.1.3 Introduction of novel platforms and technologies
                       3.3.2 Market restraint analysis
                            3.3.2.1 Ethical concerns
                            3.3.2.2 Clinical issues pertaining to development & implementation of cell therapy
                                  3.3.2.2.1 Manufacturing issues
                                  3.3.2.2.2 Genetic instability
                                  3.3.2.2.3 Condition of stem cell culture
                                  3.3.2.2.4 Stem cell distribution after transplant
                                  3.3.2.2.5 Immunological rejection
                                  3.3.2.2.6 Challenges associated with allogeneic mode of transplantation
                       3.3.3 Market opportunity analysis
                            3.3.3.1 Approval of Kymriah and Yescarta across various Asian countries
                            3.3.3.2 Developments in CAR T-cell therapy for solid tumors
                       3.3.4 Market challenge analysis
                            3.3.4.1 Operational challenges associated with cell therapy development & usage
                                  3.3.4.1.1 Volume of clinical trials for cell and gene therapy vs accessible qualified centers
                                  3.3.4.1.2 Complex patient referral pathway
                                  3.3.4.1.3 Patient treatment, selection, and evaluation
                                  3.3.4.1.4 Availability of staff vs volume of cell therapy treatments
                 3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2020
                 3.5 Business Environment Analysis
                       3.5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
                       3.5.2 Porter’s Five Forces Analysis
                 3.6 Regulatory Framework
                       3.6.1 China
                            3.6.1.1 Regulatory challenges & risk of selling unapproved cell therapies
                       3.6.2 Japan
Chapter 4 Cell Therapy Market: COVID-19 Impact analysis
                 4.1 Challenge’s analysis
                       4.1.1 Manufacturing & supply challenges
                       4.1.2 troubleshooting the manufacturing & supply challenges associated to COVID-19
                       4.1.3 Other challenges
                 4.2 Opportunities analysis
                       4.2.1 Need for development of new therapies against SARS-CoV-2
                            4.2.1.1 Role of T-cell based therapeutics in COVID-19 management
                            4.2.1.2 Role of mesenchymal cell-based therapeutics in COVID-19 management
                       4.2.2 Rise in demand for supply chain management solutions
                 4.3 Challenges in manufacturing cell therapies against COVID-19
                 4.4 Clinical Trial Analysis
                 4.5 Key Market Initiatives
Chapter 5 Asia Pacific Cell Therapy CDMOs/CMOs Landscape
                 5.1 Role of Cell Therapy CDMOs
                 5.2 Key Trends Impacting Asia Cell Therapy CDMO Market
                       5.2.1 Regulatory reforms
                       5.2.2 Expansion strategies
                       5.2.3 Rising investments
                 5.3 Manufacturing Volume Analysis
                       5.3.1 Wuxi Biologics
                       5.3.2 Samsung Biologics
                       5.3.3 GenScript
                       5.3.4 Boehringer Ingelheim
                       5.3.5 Seneca Biopharma, Inc.
                       5.3.6 Wuxi AppTech
                 5.4 Competitive Milieu
                       5.4.1 Regional network map for major players
Chapter 6 Asia Pacific Cell Therapy Market: Use Type Business Analysis
                 6.1 Market (Stem & non-stem cells): Use type movement analysis
                 6.2 Clinical Use
                       6.2.1 Market (stem & non-stem cells) for clinical use, 2017 - 2028 (USD Million)
                       6.2.2 Market (stem & non-stem cells) for clinical use, by therapeutic area
                            6.2.2.1 Malignancies
                                  6.2.2.1.1 Market (stem & non-stem cells) for malignancies, 2017 - 2028 (USD Million)
                            6.2.2.2 Musculoskeletal disorders
                                  6.2.2.2.1 Market (stem & non-stem cells) for musculoskeletal disorders, 2017 - 2028 (USD Million)
                            6.2.2.3 Autoimmune disorders
                                  6.2.2.3.1 Market (stem & non-stem cells) for autoimmune disorders, 2017 - 2028 (USD Million)
                            6.2.2.4 Dermatology
                                  6.2.2.4.1 Market (stem & non-stem cells) for dermatology, 2017 - 2028 (USD Million)
                            6.2.2.5 Others
                                  6.2.2.5.1 Market (stem & non-stem cells) for other therapeutic areas, 2017 - 2028 (USD Million)
                       6.2.3 Market (stem & non-stem cells) for clinical use, by cell type
                            6.2.3.1 Stem cell therapies
                                  6.2.3.1.1 Market, 2017 - 2028 (USD Million)
                                  6.2.3.1.2 BM, blood, & umbilical cord-derived stem cells/mesenchymal stem cells
                                       6.2.3.1.2.1 Asia Pacific BM, blood, & umbilical cord-derived stem cells/ mesenchymal stem Cells -derived stem cell therapies market, 2017 - 2028 (USD Million)
                                  6.2.3.1.3 Adipose-derived stem cell therapies
                                       6.2.3.1.3.1 Market, 2017 - 2028 (USD Million)
                                  6.2.3.1.4 Other stem cell therapies
                                       6.2.3.1.4.1 Market, 2017 - 2028 (USD Million)
                            6.2.3.2 Non-stem cell therapies
                                  6.2.3.2.1 Market, 2017 - 2028 (USD Million)
                 6.3 Research Use
                       6.3.1 Mmarket (stem & non-stem cells) for research use, 2017 - 2028 (USD Million)
Chapter 7 Asia Pacific Cell Therapy Market: Therapy Type Business Analysis
                 7.1 Market (Stem & Non-stem Cells): Therapy type movement analysis
                 7.2 Allogeneic Therapies
                       7.2.1 Market (stem & non-stem cells) for allogeneic therapies, 2017 - 2028 (USD Million)
                 7.3 Autologous Therapies
                       7.3.1 Market (stem & non-stem cells) for autologous therapies, 2017 - 2028 (USD Million)
Chapter 8 Asia Pacific Cell Therapy Market: Country Business Analysis
                 8.1 Market (Stem & Non-stem Cells) Share by Country, 2020 & 2028
                 8.2 Japan
                       8.2.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.2.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.3 China
                       8.3.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.3.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.4 India
                       8.4.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.4.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.5 Malaysia
                       8.5.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.5.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.6 South Korea
                       8.6.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.6.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.7 Philippines
                       8.7.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.7.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.8 Australia
                       8.8.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.8.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.9 Indonesia
                       8.9.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
                       8.9.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
                 8.10 Singapore
                       8.10.1 Market (stem & non-stem cells), by use type, 2017 - 2028 (USD Million)
                       8.10.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
Chapter 9 Asia Pacific Cell Therapy Market: Competitive Landscape
                 9.1 Strategy Framework
                 9.2 Company Profiles
                       9.2.1 Kolon TissueGene, Inc.
                            9.2.1.1 Company overview
                            9.2.1.2 Financial Performance
                            9.2.1.3 Product benchmarking
                            9.2.1.4 Strategic initiatives
                       9.2.2 JCR Pharmaceuticals Co., Ltd.
                            9.2.2.1 Company overview
                            9.2.2.2 Financial Performance
                            9.2.2.3 Product benchmarking
                            9.2.2.4 Strategic initiatives
                       9.2.3 MEDIPOST
                            9.2.3.1 Company overview
                            9.2.3.2 Financial Performance
                            9.2.3.3 Product benchmarking
                            9.2.3.4 Strategic initiatives
                       9.2.4 PHARMICELL Co., Ltd.
                            9.2.4.1 Company overview
                            9.2.4.2 Financial Performance
                            9.2.4.3 Product benchmarking
                            9.2.4.4 Strategic initiatives
                       9.2.5 ANTEROGEN. CO., LTD
                            9.2.5.1 Company overview
                            9.2.5.2 Financial Performance
                            9.2.5.3 Product benchmarking
                       9.2.6 Bristol-Myers Squibb Company
                            9.2.6.1 Company overview
                                  9.2.6.1.1 Celgene Corporation
                            9.2.6.2 Financial performance (Bristol-Myers Squibb)
                                  9.2.6.2.1 Financial performance (CelgeneCorporation)
                            9.2.6.3 Product benchmarking
                            9.2.6.4 Strategic initiatives
                       9.2.7 Novartis AG
                            9.2.7.1 Company overview
                            9.2.7.2 Financial Performance
                            9.2.7.3 Product benchmarking
                            9.2.7.4 Strategic initiatives
                       9.2.8 Gilead Sciences, Inc.
                            9.2.8.1 Company overview
                                  9.2.8.1.1 DAIICHI SANKYO COMPANY, LIMITED
                            9.2.8.2 Financial Performance
                                  9.2.8.2.1 Financial Performance: Daiichi Sankyo
                            9.2.8.3 Product benchmarking
                            9.2.8.4 Strategic initiatives
                       9.2.9 Curocell, Inc.
                            9.2.9.1 Company overview
                            9.2.9.2 Product benchmarking
                            9.2.9.3 Strategic initiatives
                       9.2.10 JW Therapeutics (Shanghai) Co., Ltd.
                            9.2.10.1 Company overview
                            9.2.10.2 Product benchmarking
                            9.2.10.3 Strategic initiatives
                       9.2.11 STEMPEUTICS RESEARCH PVT LTD
                            9.2.11.1 Company overview
                            9.2.11.2 Product benchmarking
                            9.2.11.3 Strategic initiatives


List of Tables

Table 1 Some approved non-CAR-T cell therapies for clinical-use
Table 2 Approved CAR-T cell therapies
Table 3 Products with RMAT Designations by the U.S. FDA
Table 4 Examples of FDA-approved regenerative medicines
Table 5 CAR T-cell resources and potential disruptions during a pandemic
Table 6 Ongoing regenerative medicine clinical trials to treat COVID-19 & related complications, as of April 14, 2020
Table 7 Registered CAR T trials for solid tumors in Singapore
Table 8 Japan cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 9 Japan cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 10 Japan cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 11 Japan stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 12 Japan cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 13 China cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 14 China cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 15 China cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 16 China stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 17 China cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 18 India cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 19 India cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 20 India cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 21 India stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 22 India cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 23 Malaysia cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 24 Malaysia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 25 Malaysia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 26 Malaysia stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 27 Malaysia cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 28 South Korea cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 29 South Korea cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 30 South Korea cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 31 South Korea stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 32 South Korea cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 33 Philippines cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 34 Philippines cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 35 Philippines cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 36 Philippines stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 37 Philippines cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 38 Australia cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 39 Australia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 40 Australia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 41 Australia stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 42 Australia cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 43 Indonesia cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 44 Indonesia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 45 Indonesia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 46 Indonesia stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 47 Indonesia cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 48 Singapore cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 49 Singapore cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 50 Singapore cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 51 Singapore stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 52 Singapore cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Initiatives by Vericel Corporation to sustain market and boost revenue through its ATMPs
Fig. 9 Number of active therapies
Fig. 10 Top targets of cell therapies for hematological malignancies, by CAR-T cell therapy type
Fig. 11 Top targets of cell therapies for solid tumors, by CAR-T cell therapy type
Fig. 12 Factors considered for regional market share analysis
Fig. 13 Market summary, 2020 (USD Million)
Fig. 14 Market trends & outlook
Fig. 15 Market segmentation and scope
Fig. 16 Market driver relevance analysis (Current & future impact)
Fig. 17 Clinical trials for cell therapy in East Asia, as of May 2021
Fig. 18 Clinical trials for cell therapy in North Asia, as of May 2021
Fig. 19 Clinical trials for cell therapy in Pacific, as of May 2021
Fig. 20 Clinical trials for cell therapy in South Asia, as of May 2021
Fig. 21 Clinical trials for cell therapy in Southeast Asia, as of May 2021
Fig. 22 Clinical trials for cell therapy in Southeast Asia
Fig. 23 Market restraint relevance analysis (Current & future impact)
Fig. 24 Clinical trials for the use of CAR T cell therapy in solid tumors: Comparison of Asian countries with rest of the world
Fig. 25 Penetration and growth prospect mapping for therapy type, 2020
Fig. 26 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 27 Porter’s Five Forces Analysis
Fig. 28 Troubleshooting the challenges associated with COVID-19: Cell therapy development programs
Fig. 29 Troubleshooting the challenges associated with COVID-19: Cell therapy manufacturing & delivery
Fig. 30 Role of cell-based therapeutics in COVID-19 management
Fig. 31 Asia Pacific cell therapy market (stem cells & non-stem cells): Use type outlook key takeaways
Fig. 32 Asia Pacific cell therapy market (stem & non-stem cells): Use type movement analysis
Fig. 33 Asia Pacific cell therapy market (stem & non-stem cells) for clinical use, 2017 - 2028 (USD Million)
Fig. 34 Asia Pacific cell therapy market (stem & non-stem cells) for malignancies market, 2017 - 2028 (USD Million)
Fig. 35 Asia Pacific cell therapy market (stem & non-stem cells) for musculoskeletal disorders, 2017 - 2028 (USD Million)
Fig. 36 Asia Pacific cell therapy market (stem & non-stem cells) for autoimmune disorders, 2017 - 2028 (USD Million)
Fig. 37 Asia Pacific cell therapy market (stem & non-stem cells) for dermatology, 2017 - 2028 (USD Million)
Fig. 38 Asia Pacific cell therapy market (stem & non-stem cells) for other therapeutic areas, 2017 - 2028 (USD Million)
Fig. 39 Asia Pacific stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 40 Asia Pacific BM, blood, & umbilical cord-derived stem cells/mesenchymal stem cells -derived stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 41 Asia Pacific adipose-derived stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 42 Asia Pacific other stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 43 Asia Pacific non-stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 44 Asia Pacific cell therapy market (stem & non-stem cells) for research use, 2017 - 2028 (USD Million)
Fig. 45 Asia Pacific cell therapy market (stem cells & non-stem cells): Therapy type outlook key takeaways
Fig. 46 Asia Pacific cell therapy market (stem & non-stem cells): Therapy type movement analysis
Fig. 47 Asia Pacific cell therapy market (stem & non-stem cells) for allogeneic therapies, 2017 - 2028 (USD Million)
Fig. 48 Asia Pacific cell therapy market (stem & non-stem cells) for autologous therapies, 2017 - 2028 (USD Million)
Fig. 49 Asia Pacific cell therapy market (stem & non-stem cells) regional outlook, 2020 & 2028
Fig. 50 Japan cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 51 China cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 52 India cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 53 Malaysia cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 54 South Korea cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 55 Philippines cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 56 Australia cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 57 Indonesia cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 58 Capabilities being developed in Singapore for cell therapy commercialization
Fig. 59 Singapore cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 60 Strategy framework

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.